Characteristics of patients with chronic heart failure in different age groups

There are indications that the severity of clinical manifestations of chronic heart failure (CHF) is related to the age of patients, with older age groups characterized by a more severe course of CHF and more significant pathological changes in instrumental and laboratory parameters. In view of the above, the aim of the present study was to compare NT-proBNP level, other basic parameters of left ventricular myocardial contractility and the results of 6-min walk test, in CHF patients of different age. We investigated these parameters by dividing the total number of subjects into subgroups of young (18-44 years), middle-aged (45-59 years) and elderly (60-74 years) age according to WHO guidelines. There were 111 patients with CHF (82 men and 29 women) aged 20 to 74 years (mean age 60.4±1.25 years). The patients were divided into three subgroups: 1st - young age (21 patients), 2nd - middle age (37 patients) and 3rd - old age (53 patients). Echocardiographic examination, 6-minute walking test, determination of NT-proBNP level in blood plasma were used during the examination. The number of patients with decreased EF (<35%) was significantly lower among young patients, while those with preserved EF was significantly higher among elderly patients. There were more patients with signs of pulmonary hypertension (high systolic pulmonary artery pressure (SPAP)) among elderly patients. The average distance walked during a 6-minute walk was relatively shorter in elderly patients, as well as a greater number of patients with higher (III-IV functional classes (FC)). The number of patients with elevated blood NT-proBNP levels as well as mean NT-proBNP levels were also relatively higher in the older age groups. Thus, the clinical course of CHF is characterized by a more severe course in elderly patients, despite the prevalence of patients with preserved EF, which is confirmed by more frequent occurrence of FC III-IV, clinical-instrumental and laboratory parameters, and is associated, at least partly, with more frequent occurrence of comorbid pathology.

1. Kirichenko A.A. Khronicheskaya serdechnaya nedostatochnost u patsientov pozhilogo i starcheskogo vozrasta. Consilium Medicum. 2014;16(10):82-86 (In Russ.)].

2. Khammad E.V., Khammad E.V., Mursalov S.U. Chronic heart failure in the elderly as a result of molecular imbalance. Modern problems of science and education. 2015;6 (In Russ.)]. URL: https://science-education.ru/ru/article/view?id=23975

3. Kuznetsova S.A., Gladkaya I.I. Znacheniye otsenki klinicheskogo sostoyaniya bol'nykh starshego vozrasta khronicheskoy serdechnoy nedostatochnost'yu na fone komorbidnoy patologii serdechno- sosudistoy sistemy / Fundamental'nyye issledovaniya. 2009;4:51-52 (In Russ)]. URL: https://fundamental-research.ru/ru/article/view?id=4447

4. McDonagh T.A., Holmer S., Raymond I. [et al.] NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Failure. 2004; 6(3):269-273. https://doi.org/10.1016/j.ejheart.2004.01.010

5. Daubert M.A., Adams K., Yow E. [et al.] NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC: Heart Failure. 2019;7(2):158-168. https:// doi.org/10.1016/j.jchf.2018.10.014

6. McDonagh T., Metra M., Adamo M. [et al.] ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599- 3726. https://doi.org/10.1093/eurheartj/ehab368

7. Budnevskiy A.V., Kravchenko A.Ya., Tokmachev R.Ye. et al. Diagnostic, prognostic and therapeutic potential of 6-minute walk test in patients with heart failure. Cardiovascular Therapy and Prevention. 2020; 19(6):2460. (in Russ.)]. https://doi.org/10.15829/1728-8800-2020-2460

8. Augustine D.X., Coates-Bradshaw L.D., Willis J. [et al.] Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2018;5(3):G11-G24. https://doi.org/10.1530/ERP-17-0071

9. Senni M., Tribouilloy C.M., Rodeheffer R.J. [et al.] Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98(21):2282-2289. https://doi.org/10.1161/01.cir.98.21.2282

10. Perutsky D.N., Obrezan A.G., Osipova O.A., Zarudsky A.A. Left atrial function in patients with heart failure. Cardiovascular Therapy and Prevention. 2022;21(6):3265. doi:10.15829/1728-8800-2022-3265. (In Russ)]. https://doi.org/10.15829/1728-8800-2022-3265

11. Efremova E.V., Shutov A.M., Borodulina E.O. The problem of comorbidity in chronic heart failure. Ulyanovsk Medico-biological Journal. 2015;4:47-53 (In Russ)].

12. Polozova E.I., Prokhorova T.A., Khokhlova L.N., Sadi A.Sh. Pathogenetic mechanisms and features of treatment of patients with chronic heart failure in conditions of comorbidity. Modern problems of science and education. 2020;4 (In Russ)]. https://doi.org/10.17513/spno.30039

13. Braunstein J.B., Anderson G.F., Gerstenblith G. et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226-1233. https://doi.org/10.1016/s0735-1097(03)00947-1